



Please type or sign (+) inside this box →

1627  
RECEIVED  
AUG 07 2002  
U.S. Patent and Trademark Office  
TECH CENTER 2000  
/SB/2K (08-00)

Approved for use through 10/31/02. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number Of Pages In This Submission

Application Number

10/052,832

Filing Date

January 15, 2002

First Named Inventor

Gregory R. MUNDY

Group Art Unit

1627

Examiner Name

Ralph J. Gitomer

Attorney Docket No.

432722002612

### ENCLOSURES (check all that apply)

Fee Transmittal Form

Assignment Papers  
(for an Application)

After Allowance Communication to Group

Fee Attached

Drawing(s)

Appeal Communication to Board of Appeals and Interferences

Amendment / Reply

Licensing-related Papers

Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)

After Final

Petition

Proprietary Information

Affidavits/declarations

Petition to Convert to a Provisional Application

Status Letter

Extension of Time Request

Power of Attorney, Revocation  
Change of Correspondence Address

Other Enclosure(s) (please identify below):  
Exhibits A-K  
Return postcard

Express Abandonment Request

Terminal Disclaimer

Information Disclosure Statement;  
PTO form 1449; and 17 references

Request for Refund

Certified Copy of Priority Document(s)

CD, Number of CD(s) \_\_\_\_\_

Response to Missing Parts/  
Incomplete Application

Remarks



25225

PATENT TRADEMARK OFFICE

Response to Missing Parts  
under 37 CFR 1.52 or 1.53

### SIGNATURE OF APPLICANT, ATTORNEY OR AGENT

Firm  
or  
Individual Name

Peng Chen  
Registration No. 43,543

Signature


July 29, 2002

### CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on July 29, 2002.

Rhea Amid


Burden Hours Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.



PATENT  
Docket No. 432722002612

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Assistant Commissioner for Patents, Washington, D.C. 20231, on July 29, 2002.

  
Rhea Amid

RECEIVED  
AUG 07 2002  
TECH CENTER 1600/2000  
B  
8/30/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Gregory R. MUNDY, et al.

Serial No.: 10/052,832

Filing Date: January 15, 2002

For: INHIBITORS OF PROTEASOMAL  
ACTIVITY FOR STIMULATING  
[BONE AND] HAIR GROWTH (AS  
AMENDED)

Examiner: GITOMER, Ralph J.

Group Art Unit: 1627

**AMENDMENT AND RESPONSE UNDER 37 C.F.R. §1.111**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

This is in response to the Office Action mailed April 29, 2002 for which a response is due on July 29, 2002. Careful consideration has been given to the grounds for rejection as contained in the Office Action, and the enclosed discussion is offered in response. Also enclosed herewith are the following exhibits:

Exhibit A: A mark-up version of the amended specification and claim 60;

Exhibit B: A copy of Declaration of George L. Mundy pursuant to 37 C.F.R. § 1.132 with the Figures 1-12 and Table 1, which was filed with the July 30, 2001 Amendment in connection with U.S. Serial No. 09/361,775;

- Exhibit C: U.S. Patent No. 6,117,887;
- Exhibit D: U.S. Patent No. 6,075,150;
- Exhibit E: U.S. Patent No. 5,847,076;
- Exhibit F: Furet et al., *Bioorg. Med. Chem. Lett.*, 11(10):1321-4 (2001) (Abstract only);
- Exhibit G: Sunwoo et al., *Clin. Cancer Res.*, 7(5):1419-28 (2001) (Abstract only);
- Exhibit H: Sun et al., *Cancer Res.*, 61(4):1280-4 (2001) (Abstract only);
- Exhibit I: Princiotta et al., *Proc. Natl. Acad. Sci. U.S.A.*, 98(2):513-8 (2001)  
(Abstract only);
- Exhibit J: U.S. Patent No. 5,693,617; and
- Exhibit K: Meng et al., *Proc. Natl. Acad. Sci. U.S.A.*, 96(18):10403-8 (1999).